Melanoma Matters29 Joulu 2025

Ep 78: MEK inhibitor trials (METRIC, NEMO, pimasertib)

Summary

So many shoutouts in this episode of Melanoma Matters!

Sapna and James engage in a lively discussion about MEK inhibitors as monotherapy treatment. They explore the METRIC, NEMO, and pimasertib trials, and discuss side effects associated with this class of therapy. Sapna clears her own confusion regarding the PDUFA date for the NEMO study, and James objects to the way the NEMO abbreviation was derived.

Keywords

targeted therapy, MEK inhibitors, METRIC, NEMO, pimasertib, NRAS, BRAF, melanoma, oncology, side effects, clinical trials, drug approval, patient care, cancer treatment, Owen, Dave Solit, Tom Newsom-Davis, Peter Hill

Takeaways

Targeted therapy is an important area of focus in oncology.

MEK inhibitors have been in development for over 15 years.

The NEMO trial aimed to evaluate binimetinib for NRAS mutant melanoma.

PFS as a primary endpoint in clinical trials.

Side effects of MEK inhibitors.

The NEMO trial faced challenges in gaining FDA approval despite positive results.

Sound Bites

"What gets you to an ASCO?"

Chapters

00:00 Can we get James to go shirtless (req fr Owen the Trainer)

04:28 MEK inhibitor trials

07:40 Dave Solit is handsome

09:50 Side Effects of MEK Inhibitors

10:52 Shoutout to Tom Newsom-Davis

12:29 Ocular Toxicity and Patient Management

16:25 METRIC study

19:33 NEMO trial

27:16 NEMO and the fate of its PDUFA date

29:03 Pimasertib: A New Player in NRAS Mutant Melanoma

34:31 Shoutout to Peter Hill & what is the #1 cause of rhabdo in Central London

Tämä jakso on lisätty Podme-palveluun avoimen RSS-syötteen kautta eikä se ole Podmen omaa tuotantoa. Siksi jakso saattaa sisältää mainontaa.

Jaksot(93)

Ep 88: Negative Adjuvant Doublet Studies (CM915, KV010, RELA098)

Melanoma Matters: Why Adjuvant Doublet Immunotherapy Fell ShortHobbies - James wishes he was surfing more This episode breaks down three negative adjuvant melanoma trials testing combination immunothe...

1 Syys 22min

Ep 86: Teaser Tudriqev (RP1) FDA Approval

James asks the big question

25 Elo 10s

Ep 87: INTerpath-001 Press Release - August 2026

In this episode, Sapna and James discuss the INTerpath-001 press release describing primary endpoint (RFS) and key secondary endpoint (DMFS) findings from the randomized phase 3 study of individualize...

25 Elo 12min

Ep 86: Tudriqev (RP1) FDA Approval

In this episode, James and Sapna debate how to pronounce the newest FDA approved treatment for melanoma: T-U-D-R-I-Q-E-VThey discuss the FDA Cell and Gene Therapy Advisory Committee's review of the si...

25 Elo 52min

Ep 85: Surgical considerations for TIL

In this episode, Sapna and James talk tv shows - The Gambler and His Cowboys, Brassic... They discuss the paper from NKI on surgical considerations for TIL harvest published in BJS in 2025. Topics of ...

28 Heinä 29min

Ep 84: Merlin CP-GEP and Castle i31-SLNB tests

In this episode, the chin dimple is front and center. James explains the wizarding home of Tintagel in Cornwall to Sapna, situated on a lovely promontory. This episode explores the latest evidence on ...

24 Heinä 35min

Ep 83: Guest Megan Othus and Time of Day Administration

James and Sapna welcome Megan Othus, Professor of Biostatistics at the Fred Hutch Cancer Center and one of the key statisticians at SWOG.Megan talks about growing up in the PNW and going East to get b...

24 Kesä 40min

Ep 82: Best of ASCO: 2026

In this episode, James & Sapna tease the size of ASCO and ESMO and number of simultaneous publications.They review the most impactful melanoma and Merkel cell carcinoma presentations from ASCO 2026, f...

13 Kesä 1h 4min